Pancreatic Steatosis, Pancreatic Cyst, Pancreatic Adenocarcinoma
Conditions
Keywords
pancreas, steatosis, cyst, cancer, adenocarcinoma, fat
Brief summary
Several pancreatic neoplastic cystic lesions, such as IPMN (intrapapilary mucinous neoplasia), cystic neuroendocrine tumors (NET) and mucinous neoplasms, present a carcinogenetic risk, though it is yet unknown if this risk is increased in patients with pancreatic steatosis (PS). The primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk. The secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.
Detailed description
Pancreatic steatosis has gained significant novel interest in the pathophysiology of PDAC and neoplastic cystic lesions. Pancreatic steatosis is the new emerging issue in pancreatology. Recently, pancreatic steatosis has gained significant novel interest in the pathophysiology of PDAC. The primary objective of the study is to determine de prevalence of pancreatic steatosis in pancreatic neoplastic cysts and if pancreatic steatosis is increased in those lesions that pose a carcinogenetic risk. Pancreatic ductal adenocarcinoma (PDAC) has a poor survival, predominantly as a result of its diagnosis in advanced stages. Pathological changes of steatosis are an independent determinant of PDAC, and these pathological changes are correlated with the attenuation of the pancreas on computed tomography (CT). The secondary objective is to evaluate the prevalence of pancreatic steatosis in pancreatic adenocarcinoma.
Interventions
DIAGNOSTIC_TESTcomputerized tomography
Little is known about the prevalence of pancreatic steatosis in patients with pancreatic cystic lesions therefore this observational study aims to clarify the data.
DIAGNOSTIC_TESTEndosonography (EUS)
EUS can better evaluate all pancreatic cysts, therefore is mandatory in this observational study.
Sponsors
Carol Davila University of Medicine and Pharmacy
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Age 18 or older * Patients with at least 1 pancreatic cystic lesion based on CT and EUS features, with a cyst size ≥ 5mm; or healthy subjects or PDAC (confirmed by histopathological exam).
Exclusion criteria
* No evidence of written informed consent * Patients with contraindications for endoscopy due to comorbidities * Metal stent in hepato-bilio-pancreatic region at time of baseline CT-imaging (vascular, luminal and biliary) * Acute pancreatitis at baseline imaging * Pancreatic surgery at baseline imaging in our department * Splenectomy * Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| increased prevalence of pancreatic steatosis in neoplastic cystic lesions | From enrollment up to 5 years | Increased prevalence of pancreatic steatosis in neoplastic cystic lesions (mostly premalignant lesions) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Increased prevalence of pancreatic steatosis in PDAC | From enrollment up to 5 years | The investigators are looking for increased prevalence of pancreatic steatosis in patients with PDAC and its association with stage of PDAC and PDAC-related mortality |
Countries
Romania
Contacts
Primary ContactCatalina Vladut, MD PhD
Outcome results
None listed